Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ETI
Enviroleach Technologies
$0.00
$0.00
$0.00
N/AN/AN/A17,860 shs
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
$17.03
-0.2%
$17.21
$15.45
$17.45
$5.22B0.271.42 million shs856,165 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$38.46
-1.7%
$39.79
$29.85
$45.00
$4.89B1.251.24 million shs689,403 shs
Linde AG stock logo
LNAGF
Linde
$218.00
$218.00
$194.75
$227.88
N/AN/A136 shsN/A
NXEOU
Nexeo Solutions
$10.50
$10.50
$8.00
$13.90
N/AN/A700 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ETI
Enviroleach Technologies
0.00%0.00%0.00%0.00%0.00%
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
-0.12%+0.18%-1.79%-0.06%+7.23%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.38%+2.89%-3.22%+13.36%+16.53%
Linde AG stock logo
LNAGF
Linde
0.00%0.00%0.00%0.00%0.00%
NXEOU
Nexeo Solutions
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ETI
Enviroleach Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.8868 of 5 stars
3.41.00.04.42.82.54.4
Linde AG stock logo
LNAGF
Linde
N/AN/AN/AN/AN/AN/AN/AN/A
NXEOU
Nexeo Solutions
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ETI
Enviroleach Technologies
N/AN/AN/AN/A
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
0.00
N/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.86
Moderate Buy$53.2938.55% Upside
Linde AG stock logo
LNAGF
Linde
N/AN/AN/AN/A
NXEOU
Nexeo Solutions
N/AN/AN/AN/A

Current Analyst Ratings

Latest NXEOU, ETI, FPE, HALO, and LNAGF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/16/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
2/29/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$54.00
2/21/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$72.00
2/21/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $50.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ETI
Enviroleach Technologies
N/AN/AN/AN/AN/AN/A
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
N/AN/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$829.25M5.89$3.14 per share12.26$0.63 per share61.05
Linde AG stock logo
LNAGF
Linde
N/AN/AN/AN/AN/AN/A
NXEOU
Nexeo Solutions
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ETI
Enviroleach Technologies
N/AN/A0.00N/AN/AN/AN/AN/AN/A
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
N/AN/A0.00N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$281.59M$2.1118.239.010.4533.96%248.20%19.13%5/7/2024 (Confirmed)
Linde AG stock logo
LNAGF
Linde
N/AN/A0.00N/AN/AN/AN/AN/A
NXEOU
Nexeo Solutions
N/AN/A0.00N/AN/AN/AN/AN/A

Latest NXEOU, ETI, FPE, HALO, and LNAGF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.64N/A-$0.64N/AN/AN/A  
2/20/2024Q4 2023
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.77$0.75-$0.02$0.85$235.25 million$230.04 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ETI
Enviroleach Technologies
N/AN/AN/AN/AN/A
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
$0.965.64%N/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Linde AG stock logo
LNAGF
Linde
N/AN/AN/AN/AN/A
NXEOU
Nexeo Solutions
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ETI
Enviroleach Technologies
N/AN/AN/A
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
N/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
17.89
6.64
5.50
Linde AG stock logo
LNAGF
Linde
N/AN/AN/A
NXEOU
Nexeo Solutions
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ETI
Enviroleach Technologies
147,000N/AN/ANot Optionable
First Trust Preferred Securities and Income ETF stock logo
FPE
First Trust Preferred Securities and Income ETF
N/A306.76 millionN/ANot Optionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
373127.05 million124.01 millionOptionable
Linde AG stock logo
LNAGF
Linde
55,646N/AN/ANot Optionable
NXEOU
Nexeo Solutions
N/AN/AN/ANot Optionable

NXEOU, ETI, FPE, HALO, and LNAGF Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Enviroleach Technologies

CNSX:ETI
EnviroMetal Technologies Inc. develops and markets technologies for the extraction of precious and other valuable metals from the mine products and electronic waste in the primary and secondary metal sectors. The company's technologies are used in the electronic waste processing industry to recover gold and other valuable metals from PCBA; and the mining industry for the recovery of gold from of ores and concentrates. It also operates E-waste and mineral processing facility. The company was formerly known as EnviroLeach Technologies Inc. and changed its name to EnviroMetal Technologies Inc. in August 2021. EnviroMetal Technologies Inc. was incorporated in 2016 and is headquartered in Burnaby, Canada.
First Trust Preferred Securities and Income ETF logo

First Trust Preferred Securities and Income ETF

NYSEARCA:FPE
The First Trust Preferred Securities and Income ETF (FPE) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is an actively managed fund that attempts to generate income by investing globally in preferred equities and income producing debt across the market cap spectrum. FPE was launched on Feb 12, 2013 and is managed by First Trust.
Halozyme Therapeutics logo

Halozyme Therapeutics

NASDAQ:HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Linde logo

Linde

OTCMKTS:LNAGF
Linde Aktiengesellschaft operates as a gases and engineering company worldwide. It operates in two divisions, Gases and Engineering. The Gases division produces and distributes atmospheric gases oxygen, nitrogen, and argon; and hydrogen, acetylene, carbon monoxide, carbon dioxide, shielding gases, noble gases, and high-purity specialty gases for use in industry, commerce, science, and research sectors, as well as develops and distributes procedures and systems for gas applications. This division also offers pharmaceutical and medical gases and services to the healthcare industry; and support services, technical equipment, and safety products, as well as develops hydrogen technology. The Engineering division provides planning, project development, and construction services with a focus on market segments, such as olefin, natural gas, air separation, and hydrogen and synthesis gas plants. This division's plants are used in various fields, including the petrochemical and chemical industries; in refineries and fertilizer plants; to recover air gases; to produce hydrogen and synthesis gases; to treat natural gas; and to produce noble gases. Linde Aktiengesellschaft is headquartered in Munich, Germany. As of October 31, 2018, Linde Aktiengesellschaft operates as a subsidiary of Linde plc.

Nexeo Solutions

OTCMKTS:NXEOU
Nexeo Solutions, Inc. operates as a chemical and plastic products distributor in North America, Europe, the Middle East, Africa, and Asia. The company operates through Chemicals, Plastics, and Environmental Services segments. It provides approximately 22,000 products used in various industries, including household, industrial and institutional, lubricants, architectural coatings, adhesives, sealants, elastomers, automotive, healthcare, personal care, oil and gas, and construction. The company was formerly known as WL Ross Holding Corp. and changed its name to Nexeo Solutions, Inc. in June 2016. Nexeo Solutions, Inc. was founded in 2014 and is based in The Woodlands, Texas.